ACA
IOVA icon

Atlas Capital Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Atlas Capital Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-950
Closed -$9.1K – 925
2022
Q3 		$9.1K Buy
+950
New +$11K ﹤0.01% 724
2022
Q2 		– Sell
-950
Closed -$15.8K – 996
2022
Q1 		$15.8K Hold
950
– – ﹤0.01% 658
2021
Q4 		$18.1K Hold
950
– – ﹤0.01% 650
2021
Q3 		$23.4K Hold
950
– – ﹤0.01% 622
2021
Q2 		$24.7K Buy
950
+300
+46% +$7.8K ﹤0.01% 627
2021
Q1 		$20.6K Hold
650
– – ﹤0.01% 601
2020
Q4 		$30.2K Buy
+650
New +$25.8K 0.01% 511
2020
Q3 		– Sell
-650
Closed -$17.8K – 435
2020
Q2 		$17.8K Buy
+650
New +$21.4K ﹤0.01% 561

Other funds holding IOVA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return